INT116903

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 32
Total Number 32
Disease Relevance 10.71
Pain Relevance 1.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Hmgcr) embryo development (Hmgcr)
Anatomy Link Frequency
myoblast 2
fibroblasts 1
external 1
red blood cell 1
Hmgcr (Mus musculus)
Pain Link Frequency Relevance Heat
Multiple sclerosis 2 95.68 Very High Very High Very High
Pain 25 95.52 Very High Very High Very High
intrathecal 6 93.64 High High
Inflammation 108 90.16 High High
imagery 5 89.92 High High
cINOD 17 86.56 High High
Spinal cord 3 83.60 Quite High
Thermal hyperalgesia 3 75.88 Quite High
fibrosis 4 74.28 Quite High
withdrawal 5 61.44 Quite High
Disease Link Frequency Relevance Heat
Macrocytic Anemia 1 99.58 Very High Very High Very High
Mevalonate Kinase Deficiency 232 99.44 Very High Very High Very High
Stress 159 99.36 Very High Very High Very High
Multiple Sclerosis 4 98.68 Very High Very High Very High
Targeted Disruption 290 98.56 Very High Very High Very High
Autoimmune Disease 4 98.44 Very High Very High Very High
Disorders Of Creatine Metabolism 9 97.40 Very High Very High Very High
Disease 295 97.24 Very High Very High Very High
Nociception 4 97.00 Very High Very High Very High
Hyperlipidemia 28 96.12 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Youssef et al. have described how an HMG-CoA inhibitor, atorvastatin, might ameliorate experimental autoimmune encephalomyelitis (EAE), the mouse model for human multiple sclerosis.
Negative_regulation (inhibitor) of HMG-CoA associated with multiple sclerosis
1) Confidence 0.43 Published 2002 Journal Mol. Interv. Section Abstract Doc Link 14993398 Disease Relevance 0.57 Pain Relevance 0.17
Necessity of CoQ10 during oral administration of HMG-CoA reductase inhibitor
Negative_regulation (inhibitor) of HMG-CoA reductase
2) Confidence 0.33 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2275764 Disease Relevance 0.16 Pain Relevance 0
Decrease in CoQ levels induced by oral administration of HMG-CoA reductase inhibitor
Negative_regulation (inhibitor) of HMG-CoA reductase
3) Confidence 0.33 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2275764 Disease Relevance 0.10 Pain Relevance 0
In this study, we investigated the effects of simvastatin, an HMG-CoA reductase inhibitor, on the viability and insulin-like growth factor-1 (IGF-1) signaling in differentiating C2C12 mouse myoblast cells.
Negative_regulation (inhibitor) of HMG-CoA reductase in myoblast
4) Confidence 0.31 Published 2007 Journal J Toxicol Sci Section Abstract Doc Link 17327694 Disease Relevance 0.47 Pain Relevance 0.10
Simvastatin reduces insulin-like growth factor-1 signaling in differentiating C2C12 mouse myoblast cells in an HMG-CoA reductase inhibition-independent manner.
Negative_regulation (reduces) of HMG-CoA reductase in myoblast
5) Confidence 0.31 Published 2007 Journal J Toxicol Sci Section Title Doc Link 17327694 Disease Relevance 0.45 Pain Relevance 0.09
These results suggest that simvastatin decreases IGF-1 signaling via a regulation of the post-translational modification of IGF-1Rbeta in an HMG-CoA reductase inhibition-independent manner.
Negative_regulation (decreases) of HMG-CoA reductase
6) Confidence 0.31 Published 2007 Journal J Toxicol Sci Section Abstract Doc Link 17327694 Disease Relevance 0.06 Pain Relevance 0
HMG-CoA reductase activity was reduced by 30% and 60% in the Abcg8+/- and Abcg8-/- mice, respectively (Figure 4b), and thus reflected the changes in mRNA expression.
Negative_regulation (reduced) of HMG-CoA reductase
7) Confidence 0.25 Published 2004 Journal BMC Med Section Body Doc Link PMC394351 Disease Relevance 0.36 Pain Relevance 0
Because cholesterol and CoQ share the same biosynthesis pathway until farnesyl pyrophosphate [34, 35], inhibition of HMG-CoA reductase, which is the rate-limiting enzyme in cholesterol biosynthesis, is likely to affect the metabolism and physiological functions of CoQ, including H2CoQ [35].
Negative_regulation (inhibition) of HMG-CoA reductase
8) Confidence 0.25 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2275764 Disease Relevance 0.11 Pain Relevance 0
Protective Effects of Coenzyme Q10 on Decreased Oxidative Stress Resistance Induced by Simvastatin

The effects of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA reductase), on oxidative stress resistance and the protective effects of coenzyme Q (CoQ) were investigated.

Negative_regulation (inhibitor) of HMG-CoA reductase associated with stress
9) Confidence 0.25 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Title Doc Link PMC2275764 Disease Relevance 0.28 Pain Relevance 0
Moreover, inhibition of mevalonate synthesis by HMG-CoA reductase inhibition with simvastatin attenuated the second phase, but not the first phase, of nociceptive response to formalin.
Negative_regulation (inhibition) of HMG-CoA reductase associated with nociception
10) Confidence 0.24 Published 2008 Journal Pain Section Abstract Doc Link 17764839 Disease Relevance 0.63 Pain Relevance 0.61
Decreased oxidative stress resistance due to oral administration of HMG-CoA reductase inhibitor
Negative_regulation (inhibitor) of HMG-CoA reductase associated with stress
11) Confidence 0.24 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2275764 Disease Relevance 0.18 Pain Relevance 0.08
Protective Effects of Coenzyme Q10 on Decreased Oxidative Stress Resistance Induced by Simvastatin

The effects of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA reductase), on oxidative stress resistance and the protective effects of coenzyme Q (CoQ) were investigated.

Negative_regulation (inhibitor) of 3-hydroxy-3-methylglutaryl CoA reductase associated with stress
12) Confidence 0.21 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Title Doc Link PMC2275764 Disease Relevance 0.27 Pain Relevance 0
Hepatic levels of GC-measured cholesterol were greatly reduced in Abcg8-/- mice compared to wild-type mice, yet mRNA levels of HMG-CoA reductase and enzyme activity are also reduced without any significant change in mRNA of the Srebps.
Negative_regulation (reduced) of HMG-CoA reductase
13) Confidence 0.19 Published 2004 Journal BMC Med Section Body Doc Link PMC394351 Disease Relevance 0.30 Pain Relevance 0.08
HMG-CoA reductase inhibition increases circulating TGF-?
Negative_regulation (inhibition) of HMG-CoA reductase
14) Confidence 0.15 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2597201 Disease Relevance 0.64 Pain Relevance 0.08
-induced Smad transcriptional activation, showing the involvement of the direct inhibition of HMG-CoA reductase (Figure 5a).
Negative_regulation (inhibition) of HMG-CoA reductase
15) Confidence 0.14 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2597201 Disease Relevance 0.57 Pain Relevance 0
HMG-CoA reductase inhibitors, such as statins, block the first step in the cholesterol biosynthetic pathway.
Negative_regulation (inhibitors) of HMG-CoA reductase
16) Confidence 0.10 Published 2008 Journal Gene Regulation and Systems Biology Section Body Doc Link PMC2745153 Disease Relevance 0.08 Pain Relevance 0
Statins block the HMG-COA reductase enzyme, which depletes cells of farnesyl pyrophosphate.
Negative_regulation (block) of HMG-COA reductase enzyme
17) Confidence 0.10 Published 2008 Journal Gene Regulation and Systems Biology Section Body Doc Link PMC2745153 Disease Relevance 0.31 Pain Relevance 0
These include Bambi, Bmp8a, Ccnd2, Lef1, Nkd2, Smad7, Wnt5a, and Wnt11 (Figure 4F, colored in red).
Negative_regulation (colored) of red
18) Confidence 0.08 Published 2008 Journal PLoS Genetics Section Body Doc Link PMC2211538 Disease Relevance 0.18 Pain Relevance 0
Using the same approach, i.e., reducing the flux through the pathway by incubating control and MKD cells with simvastatin, an inhibitor of HMG-CoA reductase, we now studied the effect on localization and activation of RhoA and Rac1.
Negative_regulation (inhibitor) of HMG-CoA reductase associated with mevalonate kinase deficiency
19) Confidence 0.07 Published 2010 Journal J Inherit Metab Dis Section Body Doc Link PMC2946549 Disease Relevance 0.63 Pain Relevance 0
Inhibition of HMG-CoA reductase, however, resulted in a stronger decrease of membrane-bound (i.e., geranylgeranylated) RhoA in MKD cells than in control cells (Houten et al 2003b).
Negative_regulation (Inhibition) of HMG-CoA reductase associated with mevalonate kinase deficiency
20) Confidence 0.07 Published 2010 Journal J Inherit Metab Dis Section Body Doc Link PMC2946549 Disease Relevance 0.39 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox